Matthew Harold G Katz

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design
    Matthew H G Katz
    Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 20:2787-95. 2013
  2. doi request reprint Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:5749-56. 2012
  3. doi request reprint Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 215:e11-8. 2012
  4. pmc Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Arch Surg 147:513-9. 2012
  5. doi request reprint Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
    J Gastrointest Surg 16:68-78; discussion 78-9. 2012
  6. pmc Adenosquamous versus adenocarcinoma of the pancreas: a population-based outcomes analysis
    Matthew Harold G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
    J Gastrointest Surg 15:165-74. 2011
  7. doi request reprint Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 18:337-44. 2011
  8. ncbi request reprint Current concepts in multimodality therapy for retroperitoneal sarcoma
    Matthew H G Katz
    The University of Texas, MD Anderson Cancer Center, Department of Surgical Oncology, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 7:159-68. 2007
  9. pmc Current status of adjuvant therapy for pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncologist 15:1205-13. 2010
  10. pmc Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 16:836-47. 2009

Detail Information

Publications11

  1. doi request reprint Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design
    Matthew H G Katz
    Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 20:2787-95. 2013
    ..Shortcomings have included an absence of staging and treatment standards and pre-existing biases with regard to the use of neoadjuvant therapy and the role of vascular resection at pancreatectomy...
  2. doi request reprint Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:5749-56. 2012
    ..In this study, the authors sought to determine the rate at which neoadjuvant therapy is associated with a reduction in the size or stage of borderline resectable tumors...
  3. doi request reprint Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 215:e11-8. 2012
    ..The technical approaches we have described here can be used as a basic foundation for operative safety and efficiency during these challenging operations...
  4. pmc Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Arch Surg 147:513-9. 2012
    ..To calculate conditional survival estimates for patients with pancreatic adenocarcinoma...
  5. doi request reprint Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
    J Gastrointest Surg 16:68-78; discussion 78-9. 2012
    ..To determine the influence of neoadjuvant chemoradiation and standardized dissection of the superior mesenteric artery upon the oncologic outcome of patients with localized pancreatic adenocarcinoma...
  6. pmc Adenosquamous versus adenocarcinoma of the pancreas: a population-based outcomes analysis
    Matthew Harold G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
    J Gastrointest Surg 15:165-74. 2011
    ..Pancreatic adenosquamous carcinoma has historically been characterized as having a more aggressive clinical course than ductal adenocarcinoma. The natural history of this disease, however, is essentially unknown...
  7. doi request reprint Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 18:337-44. 2011
    ..Standardization of surgical and pathologic techniques is crucial to the interpretation of studies evaluating adjuvant therapies for pancreatic cancer (PC)...
  8. ncbi request reprint Current concepts in multimodality therapy for retroperitoneal sarcoma
    Matthew H G Katz
    The University of Texas, MD Anderson Cancer Center, Department of Surgical Oncology, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 7:159-68. 2007
    ....
  9. pmc Current status of adjuvant therapy for pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncologist 15:1205-13. 2010
    ..Well-designed prospective trials are needed to define the optimal adjuvant or neoadjuvant therapy strategy for these patients...
  10. pmc Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 16:836-47. 2009
    ..We evaluated long-term survival and patterns of recurrence in patients treated for PC with contemporary staging and multimodality therapy...
  11. pmc Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C
    Laura A Lambert
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 16:2181-7. 2009
    ..This study analyzes the incidence and risk factors for developing neutropenia following MMC-HIPEC combined with CRS...